Soleno Therapeutics (SLNO) Net Equity Issued and Repurchased (2015 - 2023)

Soleno Therapeutics (SLNO) posted quarterly Net Equity Issued and Repurchased of -$7.1 million for Q3 2023, down 3636.32% quarter-over-quarter from -$190000.0 in Q3 2020.

Soleno Therapeutics (SLNO) Net Equity Issued and Repurchased (2015 - 2023) Analysis & Trends

Soleno Therapeutics (SLNO) has reported Net Equity Issued and Repurchased for 5 consecutive years, with -$7.1 million the latest figure, recorded in Q3 2023.

  • In Q3 2023, Net Equity Issued and Repurchased changed N/A year-over-year to -$7.1 million; the TTM figure through Dec 2024 stood at -$7.1 million (up 2.61% YoY), while the FY2025 annual figure was $215.7 million, up 44.82% from the prior year.
  • Net Equity Issued and Repurchased declined to -$7.1 million in Q3 2023 per SLNO's latest filing, from -$190000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at -$190000.0 in Q3 2020 and bottomed at -$7.1 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Soleno Therapeutics 2.74 Bn 2.49 Bn 93.41 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2023 -7.10 Mn
Sep 30, 2023 -7.10 Mn
Sep 30, 2020 -190,000.00
Sep 30, 2020 -190,000.00
Mar 31, 2017 10.00 Mn
Mar 31, 2017 10.00 Mn
Dec 31, 2016 -70,000.00
Dec 31, 2016 -70,000.00
Jun 30, 2016 70,000.00
Jun 30, 2016 70,000.00
Dec 31, 2015 194.00
Dec 31, 2015 194.00
Sep 30, 2015 1.43 Mn
Sep 30, 2015 1.43 Mn